SHARE

PODCAST May 24, 2022

Innovation in Higher Education, Perspectives from a Pharma CEO - With Dr. David Bearss of U2TAH Therapeutics Accelerator

You've Reached Your
Free Article Limit This Month
Subscribe now to get unlimited access to all Law.com OnPractice content. Your subscription is free.
Subscribe Now

Key Takeaways

  • Dr. Bearss discusses advancements in the pharmaceutical industry throughout his career, new initiatives being implemented in connection with the University of Utah, and economic development throughout the country.

This episode is part of an ongoing series where we interview leaders who are striving to grow economic development in their area. In this episode, we're joined by Dr. David Bearss, Senior Managing Director at the U2TAH Therapeutics Accelerator. Dr. Bearss discusses advancements in the pharmaceutical industry throughout his career, new initiatives being implemented in connection with the University of Utah, and economic development throughout the country.

Scott Marty, co-leader of our Life Science Industry Group, hosts the conversation.

ALM expressly disclaims any express or implied warranty regarding the OnPractice Content, including any implied warranty that the OnPractice Content is accurate, has been corrected or is otherwise free from errors.

More From Ballard Spahr

Federal Regulation for Digital Assets Could Be Coming Soon

By Scott L. Diamond Ballard Spahr July 22 , 2022

Significant federal regulation may be coming soon for cryptocurrencies, blockchain, and non-fungible tokens (NFTs).

Closing the Gate: House Adopts ENABLERS Act Amendment to 2023 NDAA

By Peter D. Hardy Ballard Spahr July 21 , 2022

Amendment Focuses on Professional “Gatekeepers” – Lawyers, Accountants, Payment Processors, and Those Providing Corporate Formation and Trust Services

Pennsylvania Cuts Corporate Income Tax Rates, Makes Other Significant Tax Changes

By Wendi L. Kotzen Ballard Spahr July 19 , 2022

Pennsylvania’s budget season just ended and Act 53 of 2022 (Act 53), made many significant changes to the Commonwealth’s business and individual taxes.

More From Pharmaceuticals

China on the Move: Proposed Pharmaceutical Regulations Would Comprehensively Reform Regulatory Landscape

By Chia-Feng Lu Greenberg Traurig July 12 , 2022

The Chinese government's past efforts to reform its pharmaceutical industry's regulatory framework can be traced back to the 2015 Opinions on the Reform of Evaluation and Approval System for Drugs and Medical Devices (2015 Opinions) and 2017 Opinions on Deepening the Reform of the Evaluation and Approval System and Inspiring Innovation of Drugs and Medical Devices.

Regulatory and Legal Enforcement in Life Sciences: 6 Trends to Watch

By George M. Karavetsos Buchanan Ingersoll & Rooney June 20 , 2022

For a number of reasons, general regulatory enforcement in the life sciences industry took a back seat throughout much of 2020 and 2021. While there were differing approaches depending on which administration was in control of the White House, much of the focus in life sciences enforcement was squarely on the COVID-19 pandemic. And while that is still the case in some respects, priorities are beginning to shift, and the industry needs to take notice.

Supreme Court Rules that Medicaid's Secondary Payer Provision Applies to Future Medical Expenses

By Robert P. Charrow Greenberg Traurig June 14 , 2022

On June 6, the Supreme Court in Gallardo v. Marstiller resolved an ambiguity in the Medicaid statute that could have significant ramifications for those seeking to settle personal injury cases involving a plaintiff who is on Medicaid.[1] The case focused on a provision in the Medicaid Act requiring states to compel Medicaid beneficiaries to assign their rights “to payment for medical care from any third party[.]”

Featured Stories
Closeclose
Search
Menu

Working...